Heather J Webb

US Patent:

6635438, Oct 21, 2003

Filed:

Nov 6, 2001

Appl. No.:

10/012762

Inventors:

Glenn Kawasaki - Seattle WA
Heather Kay Webb - San Francisco CA
Jeffrey Owens - Seattle WA
Doreen Forest - Kelso WA
Raymond Liedtke - Bellevue WA
Sobomabo Lawson - Shoreline WA
Mark Legaz - Longview WA

Assignee:

Catch, Inc. - Seattle WA

International Classification:

C12Q 126

US Classification:

435 25, 435 4, 435975, 435968, 435 15, 435 18, 530300

Abstract:

The present invention provides an enzymatic cycling assay for assessing the amount of homocysteine and/or cystathionine in a solution such as blood, blood derivatives, or urine. The assay comprises the steps of contacting the solution containing homocysteine and/or cystathionine to form a reaction mixture, with CBS, or a derivative thereof, L-serine, and CBL, or a derivative thereof, for a time period sufficient to catalyze the cyclical conversion of homocysteine form to cystathionine and the reconversion of cystathionine to homocysteine with the production of pyruvate and ammonia; determining the amount of homocysteine and/or ammonia present in the reaction mixture; and determining the amount of homocysteine and/or cystathionine present in the solution based on the amount of pyruvate and/or ammonia formed. Expression vectors and isolation procedures for CBS, or derivatives thereof, and CBL, or derivatives thereof, are also provided as well as test kits for carrying out the assay. In preferred embodiments, the assays can be conducted in 15 minutes or less, with a minimum of enzyme usage.

US Patent:

6867014, Mar 15, 2005

Filed:

Aug 28, 2003

Appl. No.:

10/651183

Inventors:

Glenn Kawasaki - Seattle WA, US
Heather Kay Webb - San Francisco CA, US
Jeffrey Owens - Seattle WA, US
Raymond Liedtke - Bellevue WA, US
Doreen Forest - Kelso WA, US
Mark Legaz - Longview WA, US
Sobomabo Lawson - Shoreline WA, US

International Classification:

C12Q001/26
C12Q001/48
C12Q001/34
C12Q001/00
G01N033/53

US Classification:

435 25, 435 15, 435 18, 435 4, 435968

Abstract:

The present invention provides an enzymatic cycling assay for assessing the amount of homocysteine and/or cystathionine in a solution such as blood, blood derivatives, or urine. The assay comprises the steps of contacting the solution containing homocysteine and/or cystathionine to form a reaction mixture, with CBS, or a derivative thereof, L-serine, and CBL, or a derivative thereof, for a time period sufficient to catalyze the cyclical conversion of homocysteine form to cystathionine and the reconversion of cystathionine to homocysteine with the production of pyruvate and ammonia; determining the amount of homocysteine and/or ammonia present in the reaction mixture; and determining the amount of homocysteine and/or cystathionine present in the solution based on the amount of pyruvate and/or ammonia formed. Expression vectors and isolation procedures for CBS, or derivatives thereof, and CBL, or derivatives thereof, are also provided as well as test kits for carrying out the assay. In preferred embodiments, the assays can be conducted in 15 minutes or less, with a minimum of enzyme usage.

US Patent:

20020156023, Oct 24, 2002

Filed:

Dec 5, 2001

Appl. No.:

10/010740

Inventors:

Jacqueline Walling - Bristol, GB
Heather Webb - San Francisco CA, US
Alan Calvert - Newcastle, GB
David Newell - Northumbria, GB

Assignee:

Tularik Inc. - South San Francisco CA

International Classification:

A61K031/7048
A61K031/704
A61K038/21
A61K031/66
A61K031/525
A61K031/517

US Classification:

514/027000, 424/085500, 514/034000, 514/266400, 514/110000, 514/414000, 514/251000, 514/449000, 424/649000, 514/492000, 514/521000

Abstract:

The present invention provides compositions and methods for treating proliferative disorders using combination therapies of lometrexol and other therapeutically active agents. The methods include administration of lometrexol with one or more therapeutically active agents where lometrexol and the therapeutically active agent(s) are delivered in a single composition, where they are administered in separate compositions in a simultaneous manner, where lometrexol is administered first, followed by the therapeutically active agent(s), as well as where the therapeutically active agent(s) is delivered first, followed by lometrexol. In preferred embodiments, the therapeutically active agent(s) has antiproliferative properties.

US Patent:

20080200467, Aug 21, 2008

Filed:

Nov 2, 2007

Appl. No.:

11/934698

Inventors:

Dinesh Patel - Fremont CA, US
Richard D. Gless - Oakland CA, US
Heather K. Webb Hsu - San Francisco CA, US
Sampath Kumar Anandan - Fremont CA, US
Bhaskar R. Aavula - Pleasanton CA, US

International Classification:

A61K 31/5375
C07C 237/00
A61K 31/164
C07D 233/54
A61P 9/00
A61P 3/10
A61P 11/00
A61K 31/4164
A61K 31/445
C07D 295/00

US Classification:

5142378, 564169, 514621, 544162, 564188, 514623, 546233, 514331, 5483381, 514399

Abstract:

Disclosed are alpha keto amide and alpha hydroxy amide compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, pulmonary, and diabetic-related diseases.

US Patent:

20080221104, Sep 11, 2008

Filed:

Nov 2, 2007

Appl. No.:

11/934642

Inventors:

Heather Kay Webb Hsu - San Francisco CA, US

International Classification:

A61K 31/4468
A61K 31/5375
A61P 29/00

US Classification:

5142375, 514329

Abstract:

Methods for reducing autoimmune induced inflammation, including rheumatoid arthritis in a subject in need of such therapy are disclosed.

US Patent:

20080221105, Sep 11, 2008

Filed:

Jan 28, 2008

Appl. No.:

12/021247

Inventors:

Heather Kay Webb Hsu - San Francisco CA, US

International Classification:

A61K 31/4468
A61P 3/00
A61K 31/5375

US Classification:

5142375, 514329

Abstract:

Compounds, compositions, and methods for inhibiting the onset of metabolic syndrome and treating related disorders in a subject in need of such therapy are disclosed.

US Patent:

20090197916, Aug 6, 2009

Filed:

Nov 4, 2008

Appl. No.:

12/264816

Inventors:

Yi-Xin (Jim) Wang - Lafayette CA, US
Heather Kay Webb Hsu - Seattle WA, US

International Classification:

A61K 31/44

US Classification:

514325

Abstract:

Compounds, compositions, and methods for inhibiting the onset of metabolic syndrome and treating related disorders in a subject in need of such therapy are disclosed.

US Patent:

20130143902, Jun 6, 2013

Filed:

Nov 30, 2012

Appl. No.:

13/691524

Inventors:

Gilead Calistoga LLC - Foster City CA, US
Heather Webb - Seattle WA, US
Brian Lannutti - Seattle WA, US

Assignee:

GILEAD CALISTOGA LLC - Foster City CA

International Classification:

C07D 473/34
A61K 45/00
A61K 31/522

US Classification:

51426321, 544277

Abstract:

Provided are methods that relate to a novel therapeutic strategy for the treatment of cancers. In particular, the method comprises administration of Compound A,or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such compound admixed with at least one pharmaceutically acceptable excipient.